Please assess the completion status of the following clinical trial:

Trial Title: Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Unresectable and/or metastatic GIST~* Currently receiving imatinib 400 mg per day for a minimum of 4 weeks prior to registration, and for no more than 6 months prior to registration. This must be the first time that the patient has been treated for metastatic and/or unresectable GIST~* For patients who received imatinib following surgery at the time of an initial diagnosis of GIST, there must be a 6 month interval between completion of imatinib and the diagnosis of metastatic GIST~* Good physical functioning (ECOG Performance Status of 0 or 1)~* Generally, good function of organ such as liver and kidneys~Exclusion Criteria:~* Disease progression during adjuvant therapy with imatinib (adjuvant treatment is treatment that is given after surgery for GIST)~* Known intolerance of imatinib at a dose of 400 mg/day or higher~* Prior systemic therapy for advanced GIST with imatinib or those who have been on imatinib for longer than 6 months for unresectable and/or metastatic disease~* Major surgery within 2 weeks prior to Day 1 of study or who have not yet recovered from prior surgery~* Use of coumadin derivatives (i.e. warfarin, acenocoumarol, phenprocoumon)~* Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation \< 2 weeks or who have not recovered from side effects of this therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Patients with blood level less than 1100 will continue imatinib 400 mg daily
- Arm B (Type: ACTIVE_COMPARATOR): Patients with blood level less than 1100 dose adjust imatinib mesylate to goal blood level ≥1100 ng/mL
- Arm C (Type: ACTIVE_COMPARATOR): Patients with blood level ≥1100 will continue imatinib 400 mg daily
- Arm D (Type: ACTIVE_COMPARATOR): Patients with tumors that harbor exon 9 mutations will continue imatinib mesylate at 400 mg or dose escalate up to 800 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).